Emerald Advisers LLC Increases Position in Alphatec Holdings, Inc. $ATEC

Emerald Advisers LLC boosted its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 10.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,807,307 shares of the medical technology company’s stock after acquiring an additional 169,578 shares during the quarter. Emerald Advisers LLC’s holdings in Alphatec were worth $19,664,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. boosted its holdings in Alphatec by 157.1% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,571 shares of the medical technology company’s stock worth $54,000 after buying an additional 1,571 shares in the last quarter. Summit Securities Group LLC acquired a new position in Alphatec during the first quarter worth approximately $29,000. Osterweis Capital Management Inc. acquired a new position in Alphatec in the second quarter valued at $37,000. FNY Investment Advisers LLC acquired a new position in shares of Alphatec in the 3rd quarter valued at about $74,000. Finally, Focus Partners Wealth acquired a new position in Alphatec during the 3rd quarter worth approximately $138,000. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Alphatec Stock Up 1.7%

Shares of ATEC stock opened at $9.74 on Tuesday. The company has a quick ratio of 1.12, a current ratio of 1.90 and a debt-to-equity ratio of 40.35. The firm has a market cap of $1.50 billion, a PE ratio of -11.88 and a beta of 0.85. The stock has a 50 day moving average of $8.36 and a 200-day moving average of $12.12. Alphatec Holdings, Inc. has a 12 month low of $6.82 and a 12 month high of $23.29.

Insider Buying and Selling at Alphatec

In related news, Director Karen K. Mcginnis sold 6,050 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $8.01, for a total value of $48,460.50. Following the sale, the director owned 94,671 shares of the company’s stock, valued at $758,314.71. The trade was a 6.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 13.48% of the company’s stock.

Wall Street Analyst Weigh In

ATEC has been the subject of a number of analyst reports. Lake Street Capital reissued a “buy” rating and issued a $15.00 price objective on shares of Alphatec in a research report on Wednesday, May 6th. Piper Sandler reiterated an “overweight” rating and set a $14.00 price objective (down from $25.00) on shares of Alphatec in a research report on Wednesday, May 6th. Stifel Nicolaus cut their price objective on Alphatec from $16.00 to $13.00 and set a “buy” rating for the company in a report on Wednesday, July 8th. TD Cowen reduced their target price on shares of Alphatec from $20.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Finally, JPMorgan Chase & Co. decreased their target price on Alphatec from $24.00 to $16.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $17.46.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.